Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan.
The attachment organelle of the human respiratory tract pathogen Mycoplasma pneumoniae is essential for colonization of the host mucosa. Furthermore, adherence-related proteins such as the major adhesin P1 and protein P30 represent vaccine candidates. Using the chimeric recombinant protein HP14/30, which combines surface-localized and adherence-involved regions of both proteins, we developed an optimized strategy to immunize guinea pigs. The vaccination protocol includes subcutaneous prime immunization followed by presentation of the antigen directly to the respiratory mucosa by two intranasal (i.n.) administrations and combination of antigen with the mucosal adjuvant chitosan. The immunization scheme induced high, consistent and long-lasting IgA levels in respiratory tract samples (BAL, nasal and throat washing fluid) from the animals. In comparison with a preimmune serum, incubation of M. pneumoniae cells with sera from these animals reduced the mean adhesion of bacteria to HeLa cells to 6%. After i.n. infection, immunized animals showed significantly decreased numbers of M. pneumoniae-specific genome copies, especially in the upper respiratory tract, in comparison with the control group. The results demonstrated that optimized immunization with the chimeric protein HP14/30 is promising for further vaccination efforts to prevent host colonization with M. pneumoniae.
TU Dresden, Institute of Medical Microbiology and Hygiene, Dresden, Germany.
Marius
M
Hausner
Anna
A
Schamberger
Wolfgang
W
Naumann
Enno
E
Jacobs
Roger
R
Dumke
D018829:Adhesins, Bacterial / Q000235:genetics / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D001422:Bacterial Adhesion; D058491:Bacterial Load; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D048271:Chitosan / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000382:microbiology; D006168:Guinea Pigs; D006367:HeLa Cells; D006801:Humans; D007279:Injections, Subcutaneous; D008168:Lung / Q000382:microbiology / Q000473:pathology; D009177:Mycoplasma pneumoniae / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D011019:Pneumonia, Mycoplasma / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D018829:Adhesins, Bacterial; D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D048271:Chitosan
Adhesin; Community-acquired pneumonia; Mycoplasma pneumoniae; Vaccination